Who is sponsoring NCT00563485?

NCT00563485 is sponsored by Hospital Authority, Hong Kong.

What condition does NCT00563485 study?

NCT00563485 studies Prostatic Hyperplasia, Urinary Retention.

What drugs are being tested in NCT00563485?

Interventions: Doxazosin GITS (Cardura XL), Terazosin (Hytrin).

What is the status of NCT00563485?

NCT00563485 is currently TERMINATED.

Last reviewed 2011-06-15 · How we verify

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily in the Successful Rate of Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

NCT00563485 NA TERMINATED

The purpose of the study is to compare two alpha blockers, terazosin and doxazosin GITS, in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.

Details

Lead sponsor	Hospital Authority, Hong Kong
Phase	NA
Status	TERMINATED
Enrolment	120
Start date	2005-10
Completion	2006-11

Conditions

Prostatic Hyperplasia
Urinary Retention

Interventions

Doxazosin GITS (Cardura XL)
Terazosin (Hytrin)

Primary outcomes

Successful rate of Trial Without Catheter (TWOC) at phase 1 — At discharge after TWOC (at the end phase one)
Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1 — From the end of phase one to eight months after successful TWOC (the end of phase 2)

Countries

China